WO2000070022A2 - Expansion ex vivo de cellules souches hematopoietiques multipotentes mammaliennes - Google Patents

Expansion ex vivo de cellules souches hematopoietiques multipotentes mammaliennes Download PDF

Info

Publication number
WO2000070022A2
WO2000070022A2 PCT/US2000/012895 US0012895W WO0070022A2 WO 2000070022 A2 WO2000070022 A2 WO 2000070022A2 US 0012895 W US0012895 W US 0012895W WO 0070022 A2 WO0070022 A2 WO 0070022A2
Authority
WO
WIPO (PCT)
Prior art keywords
cells
hsc
lif
stromal cells
expansion
Prior art date
Application number
PCT/US2000/012895
Other languages
English (en)
Other versions
WO2000070022A3 (fr
WO2000070022A9 (fr
Inventor
Chu-Chih Shih
Original Assignee
City Of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City Of Hope filed Critical City Of Hope
Priority to CA002369085A priority Critical patent/CA2369085A1/fr
Priority to IL14639700A priority patent/IL146397A0/xx
Priority to JP2000618428A priority patent/JP2002543829A/ja
Priority to AU52686/00A priority patent/AU5268600A/en
Priority to EP00937534A priority patent/EP1179049A2/fr
Publication of WO2000070022A2 publication Critical patent/WO2000070022A2/fr
Publication of WO2000070022A3 publication Critical patent/WO2000070022A3/fr
Publication of WO2000070022A9 publication Critical patent/WO2000070022A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4718—Cytokine-induced proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2303—Interleukin-3 (IL-3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1394—Bone marrow stromal cells; whole marrow

Definitions

  • the present invention is in the field of ex vivo maintenance and expansion of stem cell populations for regeneration in recipient patients.
  • hematopoietic stem cell transplantation has been conclusively proven to provide definitive therapy for a variety of malignant and non-malignant hematological diseases and myelopoietic support for patients undergoing high-dose chemotherapy.
  • HSCT hematopoietic stem cell transplantation
  • Limitations include a lack of sufficient donors, the need for either bone marrow (BM) harvest or pheresis procedures, the occurrence of a period of BM aplasia leading to severe, prolonged neutropenia and thrombocytopenia, and the potential for tumor contamination in autologous stem cell transplantation. This has resulted in an interest in the development of expansion strategies for human hematopoietic stem cells (HSC) in vi tro to overcome some of these limitations.
  • BM bone marrow
  • HSC human hematopoietic stem cells
  • ex vivo HSC generated by such expansion strategies could support multiple cycles of chemotherapy. In addition, they would also allow for transplantation of HSC to patients who are without matched donors.
  • An ex vivo expansion method also would provide for a tumor free product and facilitate the transduction of vectors into HSC for gene therapy.
  • the extended neutropenia and thrombocytopenia may be abrogated by expanded ceils from umbilical cord blood.
  • HSC human hematopoietic stem cells from highly purified subfractions of CD34 + cells possess the greatest proliferative potential resulting in large expansion of colony-forming cells (CFC) , while long-term culture initiating cells (LTC- IC) show either a slight reduction or a moderate increase.
  • CFC colony-forming cells
  • LTC- IC long-term culture initiating cells
  • HSC are defined as having both the capability of self-renewal and the ability to differentiate into at least eight distinct hematopoietic cell lineages.
  • Hematopoietic progenitors in human bone marrow can be identified by the expression of the CD34 antigen. Enrichment of pluripctent progenitor cells can be further accomplished by eliminating the CD34 + cells expressing lineage-associated antigens such as CD38 or lacking thy-1.
  • SCID-hu mice SCID-hu mice
  • SCID-hu mice SCID-hu mice
  • SCID-hu mice SCID-hu mice
  • SCID-hu mice SCID repopulating cell
  • a method for the ex vivo expansion of HSC comprises culturing HSC in the presence of a stem cell expansion promoting factor.
  • the expansion promoting factor is obtainable by culturing stromal cells in the presence of sufficient leukemia inhibitory factor to stimulate the cells to produce and secrete the expansion promoting factor.
  • the cultured and expanded HSC retain the capacity for multilineage differentiation and engraftment upon transplantation into patients.
  • a novel stem cell expansion medium which comprises a stem cell expansion promoting factor. The factor can be released from stromal cells upon activation with LIF.
  • FIG. 1 This figure illustrates the effects of 5 individual cytokines (LIF, 11-3, 11-6, SCF, and GM-CSF) on the proliferative potential of human fetal BM CD34 + thy-l + cells in vi tro .
  • Data are presented as the total number of hematopoietic cells per well (average of 15 wells) in each culture condition at each weekly time point.
  • the standard deviation for the 15 wells in the LIF-treated cultures at each weekly time point is less than 8% of the mean value.
  • FIG 2. This figure illustrates the effects of LIF in combination with other cytokines on the proliferative capacity of freshly purified human fetal BM CD34 + thy-l + cells.
  • FIG 3. This figure illustrates the kinetics of the proliferative potential of purified human fetal BM CD34 + CD38 ⁇ cells in vitro.
  • the growth factor cocktail included the cytokines 11-3, 11-6, GM-SCF, SCF, and LIF. Data are presented as the total number of hematopoietic cells per well (mean of 15 wells) at each weekly time point. The standard deviation for the 15 wells at each weekly time point is less than 12% of the mean value.
  • the kinetic data of CD34 + thy-1" cells have been superimposed with the data obtained from CD34+ CD38- cells.
  • FIG. 1 This figure illustrates hematopoietic reconstitution in the SCID-hu mice with 10,000 ex vivo- expanded CD34 + thy-l + cells from 5-week cultures.
  • Intrathymic T-cell development of ex vivo-expanded CD34 + thy-l + cells were analyzed by flow cytometry for T-cell markers, CD3, CD , and CD8, and donor marker (HLA-MA2.1-positive) . The percentage of T cells expressing detectable levels of donor-specific HLA class I antigen was recorded.
  • FIG. This figure illustrates hematopoietic reconstitution in the SCID-hu mice with 10,000 ex vivo- expanded CD34 + CD38 " celis from 5 week cultures.
  • A Intrathymic T-cell development of ex vivo-expanded CD34 + CD38 " cells. Graft cells were analyzed by flow cytometry for T-cell markers, CD3, CD4 , and CD8, and donor marker (HLA-MA2.1-positive) . The percentage of T cells expressing detectable levels of donor-specific HLA class I antigen was recorded.
  • the present invention provides the first ex vivo culture system and process for the maintenance and expansion of hematopoietic stem cells such that said expanded cells can be engrafted into patients without losing their capability for multilineage differentiation.
  • HSC have the capability of both self- renewal and the ability to differentiate into at least eight distinct hematopoietic cell lineages, such as myeloid, B-cell and T-cell lineages.
  • the ex vivo maintenance and expansion of HSC can be achieved by culturing HSC in the presence of a stem cell expansion promoting factor. This factor is obtainable by culturing stromal cells in the presence of leukemia inhibitory factor (LIF) .
  • LIF leukemia inhibitory factor
  • stromal cells produce and secrete a protein product, identified herein as a stem cell expansion promoting factor (SCEPF) , which facilitates the maintenance and expansion of hematopoietic stem cells in a culture medium.
  • SCEPF stem cell expansion promoting factor
  • mammalian hematopoietic stem cells preferably human HSC
  • HSC can be expanded ex vivo by culturing isolated HSC in a culture medium which comprises a stem cell expansion promoting factor, said factor obtainable by culturing stromal cells in a culture medium under conditions wherein said stromal cells produce and secrete said expansion promoting factor and then isolating said expansion promoting factor.
  • stromal cells initially are cultured in a culture medium in the presence of LIF to produce the stem cell expansion promoting factor, the culture medium subsequently is separated from the stromal cells and HSC are cultured in said resultant medium.
  • a method for the ex vivo maintenance and expansion of HSC comprises culturing isolated HSC in a culture system which comprises a culture medium and stromal cells in the presence of LIF.
  • the HSC are co-cultured with the stromal cells.
  • Such stromal cell 'culture is pre-established by, for example, seeding 5xl0 3 to lxlO 4 stromal cells in 96-well flat bottom plates in lOO ⁇ l of long-term culture medium.
  • the LIF is added by addition of lOO ⁇ l medium providing LIF in a concentration of at least 0.1 ng/ml of medium, preferably in the range of at least about 0.5 ng/ml to 10 ng/ml of medium.
  • the culture medium comprises any culture medium suitable for culturing hematopoietic stem cells.
  • Such media are known to those of ordinary skill in the art and comprise such components as RPMI 1640, HEPES, FCS, and common antibiotics.
  • the stem cell expansion promotion factor can be obtained by a method which comprises culturing stromal cells in a culture medium to which LIF has been added. Particularly suitable are murine stromal cells. The culturing of the stromal cells is carried out under conditions sufficient to allow the interaction of the LIF with the LIF receptor on the stromal cells such that the cells produce and secrete into the culture medium the stem cell expansion promoting factor.
  • the SCEPF then is isolated from the culture medium and added to any suitable culture medium for the ex vivo maintenance and expansion of hematopoietic stem cells.
  • Such isolation can be accomplished by harvesting the LIF treated stromal cell medium (SCM-LIF) , followed by subsequent concentration through size exclusion filtration.
  • SCM-LIF LIF treated stromal cell medium
  • LIF leukemia inhibitory factor
  • the LIF can be human LIF or other mammalian LIF, such as murine LIF.
  • This activation includes a signal transduction response in the cells which induces the production and secretion of one or more stem cell expansion promoting factors or mediators.
  • the LIF is provided in a concentration of at least about 0.1 ng/ml of medium, preferably at a concentration of at least about 0.5 ng/ml.
  • the LIF is provided at a concentration in the range of at least about 0.5 ng/ml to at least about 10 ng/ml medium, in particular at a concentration of about 10 ng/ml of medium.
  • Isolated HSC are cultured in a culture system which comprises a culture medium in the presence of a stem cell expansion promotion factor as described herein.
  • a culture system is suitable for achieving a significant expansion, such as a 150-fold expansion, of the HSC.
  • the expanded HSC retain their capability for multilineage differentiation upon introduction into the body of a patient.
  • the culture medium for the HSC further comprises at least one cytokine.
  • Preferred cytokines comprise interleukins 3 and 6 (11-3 and 11-6), stem cell factor (SCF) , granulocyte-macrophage colony stimulating factor (GM-CSF), Flt-3 ligand (FL), and thrombopoietin (TPO) .
  • SCF stem cell factor
  • GM-CSF granulocyte-macrophage colony stimulating factor
  • FL Flt-3 ligand
  • TPO thrombopoietin
  • the medium comprises 11-3 or 11-6, or a combination thereof, or it comprises TPO or CSF or a combination thereof. It has been found that the addition of at least one cytokine can enhance the expansion of HSC by at least about 55 %, preferably at least about 120 %.
  • the SCEPF responsible for assisting in the ex vivo expansion of HSC comprises at least one protein having a molecular weight in the range of about 20 - 30 kD. It has been found that the expansion promoting activity of the stem cell expansion promoting factor is not neutralized by antibodies directed to any of the cytokines listed above which can be present in the stromal cell culture medium following interaction of LIF with the stromal cell LIF receptor. Thus, the SCEPF can be further defined as comprising a protein which is distinct from these cytokines.
  • HSC can be maintained and expanded ex vivo in the presence of stromal cell medium.
  • the culture system for the HSC can comprise a culture medium collected from cultured murine stromal cells, the stromal cells having been cultured in the presence of LIF. The culturing of the stromal cells is carried out as described above such that the LIF interacts with the LIF receptor on the stromal cells and the cells produce and secrete into the culture medium the stem cell expansion promoting factor.
  • the stromal cells then are separated from the culture medium and isolated HSC subsequently are added to the resulting collected culture medium, sometimes referred to as LIF treated stromal cell medium (SCM-LIF) .
  • SCM-LIF LIF treated stromal cell medium
  • the (SCM-LIF) can be concentrated prior to use in the ex vivo culture system for the HSC.
  • Such a medium is suitable for achieving a significant expansion, such as a 150-fold expansion, of the HSC.
  • the expanded HSC retain their capability for multilineage differentiation upon introduction into the body of a patient.
  • the culture system for the HSC can further comprise at least one additional cytokine.
  • Preferred cytokines comprise those listed above.
  • isolated HSC are added to a culture system comprising the medium, stromal cells and LIF.
  • HSC were co-cultured on stromal cells in medium for ex-vivo expansion.
  • Human fetal bone, thymus and liver tissues were dissected from 18-24 week old fetuses obtained by elective abortion with approved consent. (Anatomic Gift Foundation, White Oak, GA) .
  • a sample of each received fetal tissue was stained with a panel of monoclonal antibodies (MoAbs) to HLA to establish the donor allotype.
  • the fetal tissues were used either for construction of SCID-hu mice or for preparation of human HSCs.
  • BM cell suspensions were prepared by flushing split long bones with RPMI 1620 (GIBCO/BRL, Gaithersburg, MD) containing 2% heat inactivated fetal calf serum (FCS: Gemini Bio-Products, Inc., Calabasas, CA) .
  • FCS heat inactivated fetal calf serum
  • Low density ( ⁇ 1.077 g/ml) mononuclear cells were isolated (Lymphoprep; Nycomed Pharma, Oslo, Norway) and washed twice in staining buffer (SB) consisting of Hanks' Balanced Salt Solution (HBSS) with 2% heat-inactivated FCS and 10 mmol/L
  • CD38 MoAbs were then added at 0.5 to 1 ⁇ g/10 6 cells in 0.1 to 0.3 ml SB for 20 minutes on ice. Control samples were incubated in a cocktail of FITC-labeled and PE- labeled isotype-matched MoAbs. Cells were washed twice in SB, and then resuspended in SB containing 1 ⁇ g/ml propidium iodide (Molecular Probes Inc., Eugene, OR) and sorted using the tri-laser fluorescence activated cell sorter MoFlo (Cytomation, Inc., Fort Collins, CO). Live cells (ie, those excluding propidium iodide) were always greater than 95%.
  • Sort gates were set based on mean fluoresence intensity of the isotype control sample.
  • Cells were collected in 12- or 24-well plates in RPMI 1640 containing 10% FCS and 10 mmol/1 HEPES, counted, and reanalyzed for purity in every experiment. Typically, 450000 to 500000 CD34+ thy-l+ cells were obtained from a single donor.
  • MoAbs for CD34 and CD38 were purchased from Beckton Dickinson (Mountain View, CA) .
  • MoAbs for thy-1 and isotype controls were purchased from Pharmingen (San Diego, CA) .
  • Sorted cells were cultured on a preestablished monolayer of mouse stromal cell line AC6.21.
  • Stromal cells were plated in 96-well-flat-bottom plates 1 week prior in 100 ⁇ l of long-term culture medium (LTCM) consisting of RPMI 1640, 0.05 mmol/1 2-mercaptoethanol, 10 mmol/1 HEPES, penicillin (50U/ml), streptomycin (50mg/ml), 2 mmol/1 sodium pyruvate, 2 mmol/1 glutamine, and 10% FCS.
  • Twenty CD34" thy-1 * cells were distributed in 100 ⁇ l of LTCM into each well with preestablished AC6.21 monolayer.
  • the human recombinant 11-3, 11-6, GM-CSF, SCF, and LIF were purchased from R&D Systems (Minneapolis, MN) .
  • a cytokine or combinations of cytokines support ex vivo expansion of HSCs hematopoietic cells were counted.
  • Cells were harvested without the stromal cells and analyzed for lineage content by flow cytometry by staining with MoAbs for CD19 and CD33 as well as for CD34, thy-1 or CD38. After seven weeks of ex vivo culture all cells were harvested and sorted using flowcytometry . Cells were analyzed by staining with MoAbs for CD19 and CD33 as well as for CD34, thy-1, or CD38.
  • Sorting for HSCs may be obtained by pooling all cells of all 3 populations, either CD19 , CD33 + and CD34 + thy-l + or CD34 + CD38 " and sorted for either CD34 + thy-l + or CD34 + CD38 " by flowcytometry .
  • Results show that LIF is the only cytokine that by itself can facilitate proliferation of purified human fetal BM CD34 + thy-1 ' (Fig 1) or CD34 L CD38 cells.
  • cytokines such as 11-3, II- 6, GM-SCF, and SCF can establish HSC expansion and accelerate the proliferative kinetics of purified human fetal BM CD34 + thy-1 ' cells (Fig 2) or CD34" CD38 " cells (Fig 3) .
  • the amount of CD34 * thy-l + cells in co-culture can be determined as described, and analyzed for its potential for expansion. In LIF treated wells the percentage of CD34 + thy-1 * cells in positive wells is about 7%. Because each well was initiated with 20 cells and only about 10% of the wells were CD34 + thy- lVpositive, the expected frequency of cells capable of regenerating CD34+ thy-l+ phenotype is about 1 in 200 within the CD34 * thy-1 * population. The addition of other human cytokines may facilitate this expansion but cannot support such expansion alone as is shown in Table II.
  • C.B-17 scid/scid mice were bled under sterile conditions. Mice used for human tissue transplantation were 6 to 8 weeks of age, and the construction of SCID- hu thymus/liver (thy/liv) and bone model mice were constructed as previously described. For thy/liv mice, individual pieces (1 to 2 mm) of human fetal thymus and autologous liver were placed under the kidney capsule of C.B-17 scid/scid mice and allowed to engraft for 3 months before stem cell reconstitution. For bone model mice, pieces of fetal bone were placed subcutaneously and allowed to vascuia ⁇ ze for 2 to 3 months.
  • a typical donor reconstitution derived from freshly purified CD34+ thy-l+ cells were evident m 87%, 20%, 7% and 0% of the bone crafts and 93%, 20%, 7%, and 0% of tne thy/liv crafts when transplantation was performed with 10000, 3000, 1000, and 300 cells respectively.
  • the percentage of donor derived cells m the bone grafts of reconstituted animals was 41% + 10%, 9% ⁇ 3%, 2.2% from an injected cell dose of 10000, 3000 and 1000 respectively.
  • the percentage of donor derived cells in the thymic grafts of reconstituted animals was 50% ⁇ 8%, 12% ⁇ 4%, and 3.2% from an injected cell dose of 10000, 3000 and 1C00 respectively.
  • MoAbs against HLA allotypes in combination with CD3, CD4 and CD8 were analyzed on a FACScan fluorescent cell analyzer. FITC- or PE-labeled CD19, CD33, CD3, CD4 and CD8 were purchased from Pharmingen (San Diego, CA) .
  • the expanded HSC so engrafted in the SCID-hu mice show multilineage differentiation (Fig 4).
  • Transplantation with 10000 ex vivo expanded cells shows that the engrafted human thymus contained 50% ex vivo expanded CD34+ thy-1 ' derived thymocytes. These cells were further analyzed with T-cell markers CD3, CD4 , and CD8 and showed a normal T-cell maturation pattern.
  • the engrafted human bone fragment of this SCID-hu mouse contained 39% donor-derived CD19 B cells and 16% donor- derived CD33 myeloid cells.
  • stroma l -condi tioned media from un trea ted (SCM) and LIF treated stromal cell cultures (SCM-LIF) .
  • Stromal-conditioned medium were harvested from a confluent layer of mouse stromal cell line AC6.21.
  • Stromal cells were cultured m long-term culture medium (LTCM) consisting of RPMI 1640, 0.05 mmol/1 2- ercaptoethanol, 10 mmol/1 HEPES, penicillin (50U/ml), streptomycin (50mg/ml), 2 mmol/1 sodium pyruvate, 2 mmol/1 glutamine and 10% FCS at 37 °C n a humidified atmosphere with 5% C02.
  • LTCM long-term culture medium
  • a complete medium change was made with fresh LTCM containing 10 ng/ml LIF when the stromal cell layer was confluent.
  • Conditioned medium from stromal cells was harvested every 3 days by replacing half of such media with fresh LTCM containing lOng/ml LIF for a period of up to four weeks.
  • the SCM- LIF was centrifuged at 1300 rpm for 10 minutes to remove nonadherent cells and filtered through a 0.45- ⁇ m pore filter with low protein binding (Ste ⁇ vex-HV; Millipore, Bedford, MA) .
  • SCM-LIF crude supernatants were first concentrated with a DC10 concentrator using a 100 kD molecular weight cutoff hollow-fiber cartridge (Amicon Inc, Danvers, MA) . The concentrate was then clarified by filtering with a 5 kD molecular weight cutoff cartridge. With such concentration SCM-LIF was concentrated 40-fold. SCM can be obtained similarly by culturing the stromal cells in the absence of LIF and harvesting the conditioned media the same.
  • the SCM-LIF was fractionated by molecular weight by using similar hollow-fiber cartridges (Amicon Inc, Danvers, MA) in a concentrator as described above, each with a different molecular weight cutoff.
  • each concentrator 10 ml of SCM-LIF or a fractionated sample thereof was spun in a centrifuge at 3500xG for a period of time sufficient to establish a 10 fold reduction in the volume for the retained concentrate. Following centrifugation of the concentrator both the flow-thru and retained concentrate fractions were collected from each filtration with a hollow-fiber cartridge of a particular molecular weight cutoff.
  • the flow-thru of such size exclusion filtration may have been further submitted for a second round of filtration in a concentrator in which the holow-fiber cartridge has a different molecular weight cutoff.
  • the fractions so obtained were used in a culture system comprising medium and HSC as taught in example 6 to determine the fraction containing the SCEPF activity to expand HSC.
  • the fraction comprising proteins in the range of 8kD to 30kD retained the activity for SCEPF.
  • Table III SCEPF activity in the 8-30 kD fraction from size-exclusion filtration.
  • a fraction containing proteins in the 8-30 kD range obtained through a method as described above, was subjected to additional fractionation in the same manner using concentrators with hollow-fiber tube cartridges of different molecular weight cutoffs. These fractions were used in a culture system comprising medium and HSC as taught in example 6 to determine which fraction had retained the ability to expand HSC. A fraction so obtained comprising proteins between 20- 30 kD was the only fraction showing HSC expansion activity, thus comprising the SCEPF protein.
  • Culture media containing 5%, 10% and 25% SCM-LIF are prepared by mixing fresh LTCM with appropriate amounts of unconcentrated SCM-LIF.
  • Culture media containing 50%, 100%, 200% and 400% SCM-LIF may be obtained by mixing fresh LTCM with respective amounts of concentrated SCM-LIF.
  • Freshly purified CD34+ thy-l+ cells may be cultured in LTCM containing lOng/ml of II- 1, IL-6, GM-CSF, SCF, and different concentrations of SCM-LIF.
  • a complete media exchange is made every 3 days and replaced with LTCM containing desired cytokines and amounts of SCM-LIF.
  • SCM -LI F maintains its act ivity to faci litate ex vivo expans ion of f re shly puri f ied human fetal BM CD34 * thy- l + cells in the presence of SCM
  • SCM-LIF is capable of providing a suitable environment for multipotential CD34 + thy-l + cells to differentiate into both B cells and myeloid cells similar to the stromal-based culture system as well as the ex vivo expansion of CD34 + thy-l + cells .
  • the activity of SCM-LIF to support an ex vivo culture system for expansion op HSCs may be attributed to a SCEPF (stem cell expansion promoting factor) .
  • SCEPF stem cell expansion promoting factor
  • the SCEPF does not comprise any of the prominent stem cell cytokines since neutralizing antibodies cannot block the ex vivo stem cell expansion.
  • CD34 * thy-l + cells were cultured in 200% SCM-LIF in the presence of 0.1 to lO ⁇ g/ml of neutralizing antibody against each of the cytokines from the group of GM-CSF, SCF, 11-3, 11-6, FL, and TPO the ex vivo stem cell expansion was not affected. Furthermore, culturing of the CD34 + thy-l + cells in 200% SCM in the presence of 10 ng/ml of LIF and lOng/ml of each of those cytokines either alone or in combination does not result in ex vivo expansion of HSCs.
  • GM-CSF+IL-3-IL-6-SCF+FL 100- (20/20) 18 ⁇ 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un procédé d'expansion ex vivo de cellules souches hématopoïétiques multipotentes mammaliennes qui consiste en la mise en culture de cellules souches hématopoïétiques mammaliennes isolées dans un système de culture comprenant un milieu de culture en présence d'un facteur favorisant l'expansion des cellules souches qui peut être obtenu par la mise en culture de cellules résidantes de souris en présence d'une quantité suffisante de facteur inhibiteur de leucémie pour favoriser la production et le sécrétion dudit facteur favorisant l'expansion.
PCT/US2000/012895 1999-05-14 2000-05-12 Expansion ex vivo de cellules souches hematopoietiques multipotentes mammaliennes WO2000070022A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002369085A CA2369085A1 (fr) 1999-05-14 2000-05-12 Expansion ex vivo de cellules souches hematopoietiques multipotentes mammaliennes
IL14639700A IL146397A0 (en) 1999-05-14 2000-05-12 Ex vivo expansion of mammalian hematopoietic stem cells
JP2000618428A JP2002543829A (ja) 1999-05-14 2000-05-12 哺乳動物造血幹細胞のｅｘｖｉｖｏでの増殖
AU52686/00A AU5268600A (en) 1999-05-14 2000-05-12 (ex vivo) expansion of mammalian hematopoietic stem cells
EP00937534A EP1179049A2 (fr) 1999-05-14 2000-05-12 Expansion ex vivo de cellules souches hematopoietiques multipotentes mammaliennes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13413199P 1999-05-14 1999-05-14
US60/134,131 1999-05-14

Publications (3)

Publication Number Publication Date
WO2000070022A2 true WO2000070022A2 (fr) 2000-11-23
WO2000070022A3 WO2000070022A3 (fr) 2001-05-31
WO2000070022A9 WO2000070022A9 (fr) 2001-11-22

Family

ID=22461900

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/012895 WO2000070022A2 (fr) 1999-05-14 2000-05-12 Expansion ex vivo de cellules souches hematopoietiques multipotentes mammaliennes

Country Status (7)

Country Link
US (1) US20020160512A1 (fr)
EP (1) EP1179049A2 (fr)
JP (1) JP2002543829A (fr)
AU (1) AU5268600A (fr)
CA (1) CA2369085A1 (fr)
IL (1) IL146397A0 (fr)
WO (1) WO2000070022A2 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10214095C1 (de) * 2002-03-28 2003-09-25 Bernd Karl Friedrich Kremer Dedifferenzierte, programmierbare Stammzellen monozytären Ursprungs, sowie deren Herstellung und Verwendung
EP1545603A2 (fr) * 2002-07-25 2005-06-29 The General Hospital Corporation Activation des recepteurs de l'hormone parathyroide et expansion de cellules progenitrices hematopoietiques
US7138275B2 (en) 2002-03-28 2006-11-21 Blasticon Biotechnologische Forschung Gmbh Dedifferentiated, programmable stem cells of monocytic origin, and their production and use
EP1812555A2 (fr) * 2004-10-25 2007-08-01 Cellerant Therapeutics, Inc. Procedes d'expansion de populations de cellules myeloides et utilisations
US7635477B2 (en) 2002-07-25 2009-12-22 The General Hospital Corporation Parathyroid hormone receptor activation and stem and progenitor cell expansion
US8383095B2 (en) 2006-02-14 2013-02-26 Cellerant Therapeutics, Inc. Methods and compositions for enhancing engraftment of hematopoietic stem cells
WO2015028900A1 (fr) * 2013-08-29 2015-03-05 Stempeutics Research Pvt. Ltd. Milieu conditionné dérivé de cellules stromales, procédé d'obtention de compositions dudit milieu conditionné, formulations et applications associées
US10260048B2 (en) 2010-06-15 2019-04-16 FUJIFILM Cellular Dynamics, Inc. Generation of induced pluripotent stem cells from small volumes of peripheral blood

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007536935A (ja) * 2004-05-14 2007-12-20 ベクトン・ディキンソン・アンド・カンパニー 間葉幹細胞の無血清増殖のための細胞培養環境
WO2007011088A1 (fr) * 2005-07-20 2007-01-25 Seoul National University Industry Foundation Procédé pour cultiver et faire proliférer des cellules souches hématopoïétiques et des cellules progénitrices utilisant des cellules endométriales humaines
US20080118977A1 (en) * 2006-11-22 2008-05-22 Institut De Recherche En Hematologie Et Transplantation Process to cary out a cellular cardiomyoplasty
US20080118486A1 (en) * 2006-11-22 2008-05-22 Institut De Recherche En Hematologie Et Transplantation Process to carry out a cellular cardiomyoplasty
EP2228434A4 (fr) * 2007-12-05 2013-01-23 Nissan Chemical Ind Ltd Procédé d'amplification de cellules souches hématopoïétiques avec un composé hétérocyclique
WO2012065156A2 (fr) * 2010-11-13 2012-05-18 University Of Florida Research Foundation, Inc. Développement, expansion ex vivo et analyse in vivo d'une nouvelle lignée de cellules dendritiques
CN104830772A (zh) * 2015-05-28 2015-08-12 深圳富利鑫健康产业发展有限公司 一种造血干细胞培养基及其应用和干细胞培养方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018137A1 (fr) * 1992-03-04 1993-09-16 Systemix, Inc. Culture de cellules souches hematopoietiques et leur preparation par genie genetique

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018137A1 (fr) * 1992-03-04 1993-09-16 Systemix, Inc. Culture de cellules souches hematopoietiques et leur preparation par genie genetique

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
C.-C. SHIH ET AL.: "A secreted and LIF-mediated stromal cell-derived activity that promotes ex vivo expansion of human hematopoietic stem cells." BLOOD, vol. 95, no. 6, 15 March 2000 (2000-03-15), pages 1957-1966, XP002155019 Philadelphia, US *
C.-C. SHIH ET AL.: "Long-term ex vivo maintenance and expansion of transplantable human hematopoietic stem cells." BLOOD, vol. 92, no. 10, suppl.1, 15 November 1998 (1998-11-15), pages 724a-725a, XP000971082 Philadelhia, US *
C.-C. SHIH ET AL.: "Long-term ex vivo maintenance and expansion of transplantable human hematopoietic stem cells." BLOOD, vol. 94, no. 5, 1 September 1999 (1999-09-01), pages 1623-1636, XP002155020 Philadelphia, US *
C.M. VERFAILLIE: "Soluble factors(s) produced by human bone marrow stroma increase cytokine-induced proliferation and maturation of primitive hematopoietic progenitors while preventing their terminal differentiaton." BLOOD , vol. 82, no. 7, 1 October 1993 (1993-10-01), pages 2045-2053, XP000971085 Philadelphia, US *
D.A. BREEMS ET AL.: "Stroma-contact prevents loss of hematopoietic stem cell quality during ex-vivo expansion of CD34+ mobilized peripheral blood stem cells." BLOOD, vol. 91, no. 1, 1 January 1998 (1998-01-01), pages 111-117, XP002155018 Philadelphia, US *
S.J. SZILVASSY ET AL.: "Leukemia inhibitory factor upregulates cytokine expression by a murine stromal cell line enabling the maintenance of highly enriched competitive repopulating stem cells." BLOOD, vol. 87, no. 11, 1 June 1996 (1996-06-01), pages 4618-4628, XP000971084 Philadelphia, US *

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517686B2 (en) 2002-03-28 2009-04-14 Blasticon Biotechnologische Forschung Gmbh Dedifferentiated, programmable stem cells of monocytic origin, and their production and use
DE10214095C1 (de) * 2002-03-28 2003-09-25 Bernd Karl Friedrich Kremer Dedifferenzierte, programmierbare Stammzellen monozytären Ursprungs, sowie deren Herstellung und Verwendung
US7553663B2 (en) 2002-03-28 2009-06-30 Blasticon Biotechnologische Forschung Gmbh Dedifferentiated, programmable stem cells of monocytic origin, and their production and use
US7553660B2 (en) 2002-03-28 2009-06-30 Blasticon Biotechnologische Forschung Gmbh Dedifferentiated, programmable stem cells of monocytic origin, and their production and use
US7138275B2 (en) 2002-03-28 2006-11-21 Blasticon Biotechnologische Forschung Gmbh Dedifferentiated, programmable stem cells of monocytic origin, and their production and use
US7776334B2 (en) 2002-07-25 2010-08-17 The General Hospital Corporation Parathyroid hormone receptor activation and hematopoietic progenitor cell expansion
US8309095B2 (en) 2002-07-25 2012-11-13 The General Hospital Corporation Parathyroid hormone receptor activation and stem and progenitor cell expansion
US7429383B2 (en) 2002-07-25 2008-09-30 The General Hospital Corporation Parathyroid hormone receptor activation and hematopoietic progenitor cell expansion
JP4750416B2 (ja) * 2002-07-25 2011-08-17 ザ ジェネラル ホスピタル コーポレイション 副甲状腺ホルモン受容体の活性化と造血前駆細胞の増殖
EP1545603A4 (fr) * 2002-07-25 2006-08-23 Gen Hospital Corp Activation des recepteurs de l'hormone parathyroide et expansion de cellules progenitrices hematopoietiques
JP2006512897A (ja) * 2002-07-25 2006-04-20 ザ・ジェネラル・ホスピタル・コーポレイション 副甲状腺ホルモン受容体の活性化と造血前駆細胞の増殖
US7635477B2 (en) 2002-07-25 2009-12-22 The General Hospital Corporation Parathyroid hormone receptor activation and stem and progenitor cell expansion
EP1545603A2 (fr) * 2002-07-25 2005-06-29 The General Hospital Corporation Activation des recepteurs de l'hormone parathyroide et expansion de cellules progenitrices hematopoietiques
US7943136B2 (en) 2002-07-25 2011-05-17 The General Hospital Corporation Parathyroid hormone receptor activation and stem and progenitor cell expansion
EP1812555A4 (fr) * 2004-10-25 2009-05-13 Cellerant Therapeutics Inc Procedes d'expansion de populations de cellules myeloides et utilisations
US8252587B2 (en) 2004-10-25 2012-08-28 Celerant Therapeutics, Inc. Methods of expanding myeloid cell populations and uses thereof
EP1812555A2 (fr) * 2004-10-25 2007-08-01 Cellerant Therapeutics, Inc. Procedes d'expansion de populations de cellules myeloides et utilisations
US8481315B2 (en) 2004-10-25 2013-07-09 Cellerant Therapeutics, Inc. Methods of expanding myeloid cell populations and uses thereof
EP2626415A3 (fr) * 2004-10-25 2014-04-16 Cellerant Therapeutics, Inc. Procédés d'expansion de populations de cellules myéloïdes et leurs utilisations
US8877495B2 (en) 2004-10-25 2014-11-04 Cellerant Therapeutics, Inc. Methods of expanding myeloid cell populations and uses thereof
NO342460B1 (no) * 2004-10-25 2018-05-22 Cellerant Therapeutics Inc Fremgangsmåte for å ekspandere myeloide cellepopulasjoner, og anvendelser derav
US10260044B1 (en) 2004-10-25 2019-04-16 Cellerant Therapeutic, Inc. Methods of expanding myeloid cell populations and uses thereof
US8383095B2 (en) 2006-02-14 2013-02-26 Cellerant Therapeutics, Inc. Methods and compositions for enhancing engraftment of hematopoietic stem cells
US10260048B2 (en) 2010-06-15 2019-04-16 FUJIFILM Cellular Dynamics, Inc. Generation of induced pluripotent stem cells from small volumes of peripheral blood
WO2015028900A1 (fr) * 2013-08-29 2015-03-05 Stempeutics Research Pvt. Ltd. Milieu conditionné dérivé de cellules stromales, procédé d'obtention de compositions dudit milieu conditionné, formulations et applications associées
CN105473709A (zh) * 2013-08-29 2016-04-06 斯蒂姆普优提克斯个人研究有限公司 基质细胞来源的条件培养基、获得所述条件培养基组合物的方法、其制剂及应用

Also Published As

Publication number Publication date
WO2000070022A3 (fr) 2001-05-31
EP1179049A2 (fr) 2002-02-13
US20020160512A1 (en) 2002-10-31
IL146397A0 (en) 2002-07-25
CA2369085A1 (fr) 2000-11-23
AU5268600A (en) 2000-12-05
JP2002543829A (ja) 2002-12-24
WO2000070022A9 (fr) 2001-11-22

Similar Documents

Publication Publication Date Title
CN107922925B (zh) 用于自然杀伤细胞扩增的方法
US5681559A (en) Method for producing a highly enriched population of hematopoietic stem cells
US5665557A (en) Method of purifying a population of cells enriched for hematopoietic stem cells populations of cells obtained thereby and methods of use thereof
EP1458854B1 (fr) Compositions cellulaires et procedes de preparation et d'utilisation associes
Randall et al. Expression of murine CD38 defines a population of long-term reconstituting hematopoietic stem cells
WO1996040875A1 (fr) Procedes d'obtention de compositions enrichies en cellules souches hematopoietiques et anticorps utilises a cet effet
US20020160512A1 (en) Ex vivo expansion of mammalian hematopoietic stem cells
JPH11514879A (ja) 原始ヒト幹細胞を有するＭｐ１リガンドの使用法
WO2005097979A2 (fr) Procedes et compositions destines a l'obtention de cellules souches hematopoietiques derivees de cellules souches embryonnaires et utilisations
AU7721194A (en) Genetically modified human hematopoietic stem cells and their progeny
JP2001525176A (ja) Ｃｄ７＋ｃｄ３４−ｌｉｎ−造血細胞を単離し、使用する方法
JPH08511935A (ja) 選択的細胞増殖
Goan et al. The severe combined immunodeficient-human peripheral blood stem cell (SCID-huPBSC) mouse: a xenotransplant model for huPBSC-initiated hematopoiesis
US20030100107A1 (en) Compositions and methods for generating differentiated human cells
WO2022228539A1 (fr) Procédé de préparation de cellules car-cik ayant une proportion élevée de cellules nkt, et son application
WO2018106610A1 (fr) Procédé fondé sur des billes immunomagnétiques pour enrichir des cellules souches à partir de tissu hématopoïétique entier
JP3917652B2 (ja) 造血促進細胞及びその使用
Beaujean Methods of CD34+ cell separation: comparative analysis
DE69530980T2 (de) Population von mit myeloid-und/oder lymphoid-vorläufern angereicherten zellen und verfahren zur ihrer gewinnung und verwendung
US20020098521A1 (en) Method and marker for the isolation of human multipotent hematopoietic stem cells
Roberts et al. Impact of cell culture technology on transfusion medicine
WO1995002685A1 (fr) Culture sans serum de cellules souches
Berson et al. Selection of murine lymphoid and hematopoietic cells using polystyrene tissue culture devices containing covalently immobilized antibody
Heimfeld et al. The CEPRATE SC system: Technology, clinical development and future directions
Schubert et al. 73: Human Hematopoietic Progenitors with Slow Divisional Kinetics Reconstitute T Cells in Thymus, B Cells in Lymph Nodes and Myeloid Cells in Marrow of NOD/SCID Mouse Model and Represent the Most Primitive Fraction

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2369085

Country of ref document: CA

Ref document number: 2369085

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2000 618428

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/A/2001/011722

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 52686/00

Country of ref document: AU

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/5-5/5, DRAWINGS, REPLACED BY NEW PAGES 1/5-5/5; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 2000937534

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000937534

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000937534

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642